No profile data available.
Autolus Therapeutics plc (AUTL) is a healthcare company in the additional cancer treatment drugs industry, based in London, United Kingdom, with about 647 full-time employees.
It reported revenue of $75.39 million for fiscal year 2025, up 644.9% from fiscal year 2024, and net income of -$287.53 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $45.69 million, up 118.4% from a year before. United States of America was its largest region in fiscal year 2025, with 100% of revenue. Its market capitalization was $417.84 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
Autolus Therapeutics reported $75.39 million in revenue for fiscal year 2025, up 644.9% from $10.12 million in fiscal year 2024. In Q2 2026 revenue was $45.69 million.
United States of America: 100% of revenue by region in fiscal year 2025, followed by Europe (under 1%).
$417.84 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Allogene Therapeutics, Inc. (ALLO), Arvinas, Inc. (ARVN), Editas Medicine, Inc. (EDIT), Aura Biosciences, Inc. (AURA).